Luseogliflozin (hydrate) Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Luseogliflozin hydrate, which is an SGLT2 inhibitor approved in Japan in March 2014 for the treatment of type 2 diabetes, was discovered by Taisho Pharmaceutical and jointly developed and marketed with Novartis as Lusefi®. Luseogliflozin selectively binds and inhibits human SGLT2 with a Ki of 1.10 nM and IC50 value of 2.26 nM.

Luseogliflozin (hydrate) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Luseogliflozin (hydrate) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Lynnchem	86-(0)29-85992781 17792393971	info@lynnchem.com	China	4587	58
Novachemistry	44-20819178-90 02081917890	info@novachemistry.com	United Kingdom	4381	58
Suzhou Haiben Pharmaceutical Co., Ltd	14760821013 13564957716	1816280386@qq.com	China	8045	58
TargetMol Chemicals Inc.	15002134094	marketing@targetmol.cn	China	19699	58

---

• Luseogliflozin (hydrate)
• (2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol:hydrate
• TS 071 hydrate
• 1152425-66-5